Quantcast

Novartis Buys Up Generic Drug Makers

Get the WebProNews Newsletter:


[ Business]

Novartis is buying generic-drug makers Eon Labs and Hexal for a total of $8.3 billion in cash.

This will make Novartis the largest maker of generic medecines in the world.

According to a Bloomberg News article,

“Novartis, Europe’s fourth-biggest pharmaceutical company, will pay 5.65 billion euros ($7.4 billion) for closely held Hexal and a 67.7 percent stake in Eon. The Basel, Switzerland-based company will start a tender offer to acquire the rest of Eon for $31 a share, or about $1 billion.

Chief Executive Daniel Vasella is seeking 10 percent of the generics market with the purchase, Novartis’ biggest since the firm was created in a 1996 merger, he said. Novartis’ Sandoz generics unit, its slowest-growing division last year, will surpass Israel’s Teva Pharmaceutical Industries in a market Vasella expects to grow to $100 billion in sales by 2010.”

“The generics area was a problem for Novartis, and with this acquisition they have resolved that problem with a quantum leap,” said Swisscanto Asset Management portfolio manager Dieter Winet.

WebProNews | Breaking eBusiness News
Your source for investigative ebusiness reporting and breaking news.

Novartis Buys Up Generic Drug Makers
Comments Off on Novartis Buys Up Generic Drug Makers
Top Rated White Papers and Resources

Comments are closed.

  • Join for Access to Our Exclusive Web Tools
  • Sidebar Top
  • Sidebar Middle
  • Sign Up For The Free Newsletter
  • Sidebar Bottom